Genetics/Genomics News

Angiotensin receptor blockers and beta-blockers slow down the expansion of the aorta in patients with Marfan syndrome and no previous aortic surgery, according to data reported at the European Society of Cardiology Congress.

A validated genome-wide polygenic risk score predicted clinically meaningful absolute risk for sudden arrhythmic death in a cohort of patients with CAD without severe left ventricular dysfunction, researchers reported.

A combined monogenic and polygenic risk assessment for CAD can identify individuals at high inherited risk before overt manifestation of traditional risk factors, potentially improving clinician decision-making on preventive interventions.

Data from a genetics-based study show PCSK9 inhibition does not affect cognition function or dementia risk; however, statin use may be associated with some impaired cognitive performance that is outweighed by any CV benefits.

Maintaining optimal CV health by following the American Heart Association’s Life’s Simple 7 protected people from stroke, even among those at high genetic risk, data from a long-term analysis show.

Researchers using RNA sequencing have identified unique cell and immune system signatures in tissue samples of children with congenital heart disease, offering a rare opportunity to better understand the origins of a complex disease.

Cardiologists should work with experienced centers performing genetic testing to identify and manage inherited cardiac conditions in young athletes and inform patients of risks and benefits, according to a new joint scientific statement.

Genetic inhibition of HMG-CoA reductase, a state that mimics long-term statin use, was associated with greater risk for developing cataract compared with individuals without genetic inhibition, researchers reported.

In a cohort of patients with familial hypercholesterolemia, women were less likely than men to receive high-intensity treatment and reach LDL goals, according to data presented at the National Lipid Association Scientific Sessions.

Heart transplant is the definitive treatment option for patients with advanced HF, yet allograft rejection and injury remain impediments to posttransplant survival despite continued advances in posttransplant outcomes.